EBRO 2017

The EXPERT-C trial – Results

No significant improvement in PFS and OS in the KRAS/BRAF WT group (median follow-up 63.8 months)

100

100

80

80

60

60

%

%

HR 0.62 (0.29-1.35) p=0.23

HR 0.56 (0.23-1.38) p=0.20

40

40

20

20

CAPOX CAPOX-C

CAPOX CAPOX-C

PFS

OS

0

0

0

1

2

3

4

5

6

7

8

0

1

2

3

4

5

6

7

8

Time from randomisation (years)

Time from randomisation (years)

Sclafani, ESMO 2013